ResearcherMater HospitalActive in the last 2 years
Mark Taylor
Matched on ORCID iD 0000-0002-2633-4194; OpenAlex author ID A5101588136, A5121497329. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 2 papers
Papers 12
- Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Co-author DOI 10.1016/j.ejca.2026.116592↗
- Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic cancer. Co-author DOI 10.1016/j.ejpb.2025.114937↗
- Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Co-author DOI 10.1002/cjp2.192↗
- Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.06.003↗
- Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatmen… Co-author DOI 10.1016/j.ejpb.2021.05.018↗
- Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2021.07.020↗
- Comment on "Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position". Co-author DOI 10.1038/s41416-020-01132-9↗
- An ultrasound responsive microbubble-liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejpb.2020.10.012↗
- Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2018.04.018↗
- Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2017.07.040↗
- Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. Co-author DOI 10.1016/j.biomaterials.2015.11.033↗
- Ca19-9 and pancreatic cancer: Is it really that good? First author DOI 10.3978/j.issn.2078-6891.2012.016↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- A. P. McHale · 8 shared papers, 2016–2026 · strength 0.92
- Paper Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic canc… DOI 10.1016/j.ejpb.2025.114937↗
- Paper Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation… DOI 10.1016/j.ejpb.2021.05.018↗
- Paper Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. DOI 10.1016/j.canlet.2021.06.003↗
- Heather Nesbitt · 7 shared papers, 2016–2026 · strength 0.81
- Paper Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic canc… DOI 10.1016/j.ejpb.2025.114937↗
- Paper Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation… DOI 10.1016/j.ejpb.2021.05.018↗
- Paper Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. DOI 10.1016/j.canlet.2021.06.003↗
- Keiran A. Logan · 6 shared papers, 2018–2026 · strength 0.81
- Paper Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic canc… DOI 10.1016/j.ejpb.2025.114937↗
- Paper Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation… DOI 10.1016/j.ejpb.2021.05.018↗
- Paper Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. DOI 10.1016/j.canlet.2021.06.003↗
- John F. Callan · 6 shared papers, 2016–2021 · strength 0.51
- Paper Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. DOI 10.1016/j.canlet.2021.06.003↗
- Paper Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer. DOI 10.1016/j.jconrel.2021.07.020↗
- Paper An ultrasound responsive microbubble-liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic can… DOI 10.1016/j.ejpb.2020.10.012↗
- John F. Callan · 2 shared papers, 2021–2026 · strength 0.40
- Paper Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic canc… DOI 10.1016/j.ejpb.2025.114937↗
- Paper Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation… DOI 10.1016/j.ejpb.2021.05.018↗
- Jinhui Gao · 3 shared papers, 2020–2021 · strength 0.36
- Paper Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation… DOI 10.1016/j.ejpb.2021.05.018↗
- Paper Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. DOI 10.1016/j.canlet.2021.06.003↗
- Paper An ultrasound responsive microbubble-liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic can… DOI 10.1016/j.ejpb.2020.10.012↗
- Paul J Kelly · 3 shared papers, 2017–2021 · strength 0.27
- Paper Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-anal… DOI 10.1002/cjp2.192↗
- Paper Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer. DOI 10.1016/j.jconrel.2018.04.018↗
- Paper Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancre… DOI 10.1016/j.jconrel.2017.07.040↗
- Jack Wright · 1 shared paper, 2026 · strength 0.27
- Annabelle Boughey · 1 shared paper, 2026 · strength 0.22
- Paula Ghaneh · 1 shared paper, 2026 · strength 0.22
- Kofi W. Oppong · 1 shared paper, 2026 · strength 0.22
- Tejinderjit Athwal · 1 shared paper, 2026 · strength 0.22
- Andrew Malvern Smith · 1 shared paper, 2026 · strength 0.22
- Guruprasad Padur Aithal · 1 shared paper, 2026 · strength 0.22
- Phillip J. Hopley · 1 shared paper, 2026 · strength 0.22
- Zaed Z. R. Hamady · 1 shared paper, 2026 · strength 0.22
- William Greenhalf · 1 shared paper, 2026 · strength 0.22
- Stephen P. Pereira · 1 shared paper, 2026 · strength 0.22
- Christopher Michael Halloran · 1 shared paper, 2026 · strength 0.22
- Eithne Costello · 1 shared paper, 2026 · strength 0.22
- Ali Raza Arshad · 1 shared paper, 2021 · strength 0.17
- John M. Primrose · 1 shared paper, 2021 · strength 0.17
- Ashley Robert Dennison · 1 shared paper, 2021 · strength 0.17
- Andrew J. McGuigan · 1 shared paper, 2021 · strength 0.15
- Richard Calvin Turkington · 1 shared paper, 2021 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.